CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Zepbound Outperforms CagriSema in Head to Head Phase III Obesity Trial Novo Nordisk's CagriSema Leads to Superior Weight Loss in REDEFINE 1 Trial Subcutaneous Cagrilintide, Semaglutide Shows Significant Weight Loss in Type 2 Diabetes Trial Pharmacy Times Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth